In several studies, low spirometric levels have been shown to increase the success rates of smoking cessation, whereas other studies have indicated that pulmonary function has no effects on quitting smoking. Given the fact that there are contradictory results on this subject, we aimed to investigate the effect of identifying airway obstruction via spirometry and its explanation to subjects on the success rate of smoking cessation in the short term. METHODS: Subjects who were admitted to the smoking cessation out-patient clinic, underwent pulmonary function tests (PFTs) and completed at least 3 months of the cessation program following their admittance were included in the study. At the first interview, all subjects were asked about their comorbid diseases and smoking habits. PFTs were performed. Subjects who had an obstruction on PFT were informed that their condition was smoking-related, and that further deterioration could be prevented following smoking cessation. Then the smoking cessation date was determined together with the subject, and one of the smoking cessation medicines was prescribed. All subjects were given control appointments twice for the first month and once per month for the following 2-month follow-up period. Subjects who had CO levels between 0 and 5 parts per million were considered as nonsmokers. RESULTS: The mean age of the 563 subjects was 41.9 ؎ 12.1 y 340 subjects (60.4%) were male. A total of 162 subjects (28.8%) came to the follow-up visits following the first interview. The success of smoking cessation for 3 months was 11.3% for all subjects and 39.5% for subjects who came to follow-up visits. Of the subjects with obstruction on PFT; 22.8% stopped smoking, whereas 8.4% of the subjects without obstruction did so (P < .001). The percentage of subjects with obstruction on PFT was significantly higher (P < .001) and the FEV 1 % (P ‫؍‬ .005), FEV 1 /FVC (P < .001), and forced expiratory flow 25-75% (P ‫؍‬ .008) levels were significantly lower in the quitters compared with the non-quitters. Logistic regression analysis showed that age (P ‫؍‬ .001) and the presence of obstruction on PFT (P ‫؍‬ .029) were independent variables. CONCLUSIONS: Advanced age and the presence of obstruction on PFT increase the success of smoking cessation. Pulmonary function tests should be performed on all patients who apply to smoking cessation out-patient clinics, and patients should be informed about their condition.
Introduction
COPD is one of the leading causes of mortality in the world. COPD, which was the 5th leading cause of death worldwide in 2002, is expected to rise to 4th place by 2030. 1 Smoking is the most important recognized risk factor for COPD. 2 It was first shown by Fletcher and Peto in 1977 3 that there was a decrease in mortality and annual FEV 1 loss in subjects with COPD after smoking cessation; these findings were supported by other researchers in the following years. [4] [5] [6] Based on these findings, the Global Initiative for Chronic Obstructive Lung Diseases (GOLD), the American Thoracic Society, and the European Respiratory Society also recommend smoking cessation as the first line option for preventing and treating COPD. 2, 7 Given the fact that there are contradictory results on this subject, we aimed to determine the effect of identifying airway obstruction via spirometry and sharing this information with subjects on the success rate of smoking cessation in the short term.
The most effective method for smoking cessation is the multidisciplinary approach, which encompasses psychological, behavioral and pharmacologic therapies. [8] [9] [10] According to a meta-analysis, which evaluated the success of smoking cessation treatments in subjects with COPD, the success of smoking cessation within 6 -12 months varied between 13.7 and 34.5% for pharmacologic treatment with behavioral therapy. 11 Although subjects with COPD who received the recommended treatments for smoking cessation were expected to be more successful in smoking cessation due to their symptoms, one study showed no difference in the motivation and success for smoking cessation between COPD and non-COPD subjects. 12 According to another study, subjects with COPD who quit smoking had lower pulmonary function test (PFT) values compared with non-quitters. 13 Spirometric measurement is the most important tool for COPD diagnosis. 2 Many patients with COPD learn about their disease during screening tests or at smoking cessation clinics. In several studies, it has been shown that low spirometric values and sharing of this information with subjects increase the success rates of smoking cessation. [14] [15] [16] [17] [18] Other studies have indicated that sharing information with the subject following the identification of an obstruction on the PFT has no effect on smoking cessation. 19, 20 According to 2 reviews, which evaluated similar studies, there is insufficient evidence for the positive effects of spirometry on the success of smoking cessation. 21, 22 
Methods

Study Design
This research was a retrospective cohort study. Our primary outcome was smoking cessation success for 3 months. Ethical approval was obtained from the local ethics committee of our teaching and research hospital (13.01.2015; 89513307/1009/390; registration number 17). The study plan was made in accordance with the World Medical Association Declaration of Helsinki (2008).
Subjects
Subjects who applied to the smoking cessation out-patient clinic of our hospital between January 2012 and September 2014, underwent PFT, and completed Ն3 months of the cessation program following their admittance were included in the study. Patients who failed to perform PFT were excluded from the study.
Procedures
In the first interview, all subjects were asked about their comorbid diseases and smoking habits. Their smoking history was quantified in pack-years. The Fagerström test was used to assess the nicotine dependence scores of the subjects. 23 The Hospital Anxiety and Depression Scale test was carried out to determine depression and anxiety scores. 24 The physical examinations of the subjects were performed by a physician. PFTs were performed (Sensor Medics Vi-Max 22, CareFusion, San Diego, California) according to the American Thoracic Society/European Respiratory Society standards of spirometry. 25 Obstruction on the PFT was diagnosed according to GOLD criteria (ie, post-bronchodilator FEV 1 Ͻ80% of predicted and FEV 1 /FVC Ͻ70%. 2 Small airway obstruction was diagnosed using forced expiratory flow 25-75% (FEF 25-75% ) values Ͻ65% of predicted and FEV 1 /FVC Ͼ70%. 26 Subjects who had an obstruction or small airway obstruction on PFT were informed that their condition was smoking-related but that progressive deterioration could be prevented by smoking cessation. The study by Fletcher and Peto 3 was shown as an example. The subjects who had normal spirometric measurement were also informed about their pulmonary function and that they could protect this condition by smoking cessation.
QUICK LOOK
Current knowledge
There is insufficient evidence for the positive effects of spirometry on the success of smoking cessation. There are contradictory results in previous studies.
What this paper contributes to our knowledge
Advanced age and the presence of obstruction in pulmonary function testing increase the success of smoking cessation. All patients who are admitted to smoking cessation out-patient clinics should have pulmonary function tests performed and be informed about their condition.
The carbon monoxide (CO) level in expired air was measured (Bedfont Pico Smokerlyser, coVita, Haddonfield, New Jersey), and chest radiographs were taken. The same physician performed interviews with subjects, interpreted the PFT, and measured the CO levels in the expired air. Then a smoking cessation date was determined together with the subject, and one of the smoking cessation medicines (bupropion, varenicline, or nicotine replacement therapy) was prescribed. Because the national Social Security Institution in Turkey does not cover the costs of pharmacologic treatments, the subjects paid for their own treatment costs.
All subjects were given 2 control appointments for the first month and once a month thereafter for the following 2 months of follow-up. During the control visits, subjects were questioned about their smoking status, and any adverse effects of the medication. The CO levels in their expired air were measured. Subjects who had CO levels between 0 and 5 parts per million (ppm) were considered quitters, and subjects who had CO levels Ͼ6 ppm were considered non-quitters. 27, 28 Subjects who did not attend the follow-up visits were also considered non-quitters. The collected data were entered into the hospital registration system. Analyses were performed after all subjects had been followed up for 3 months.
Statistical Analysis
Data from the standardized medical reports were transferred to SPSS 17.0 (SPSS, Chicago, Illinois) software by the lead researcher. A chi-square test was used for comparison of categorical variables between groups. To compare means between quitters and non-quitters, a t test was used, and descriptive statistics were given as mean Ϯ SD. P Ͻ .05 was accepted as statistically significant for all measures. A multivariate logistic regression analysis was used to identify the independent factors that affect smoking cessation.
Results
A total of 699 patients applied to the smoking cessation out-patient clinic of our hospital between January 2012 and September 2014. Of the 639 patients who completed at least 3 months of the cessation program following their admittance, 563 subjects who properly performed PFTs were included in the study (Fig. 1) .
The mean age of the 563 subjects was 41.9 Ϯ 12.1 y; 340 (60.4%) were male, and 223 (39.6%) were female. The mean Fagerström score was 6.1 Ϯ 2.3. The mean number of pack-years was 26.9 Ϯ 16.2. The mean CO level was 14.6 Ϯ 8.2 ppm. The mean percent-of-predicted FEV 1 was 88.8 Ϯ 17.5%. The mean anxiety score was 9.7 Ϯ 4.5, and the mean depression score was 7.7 Ϯ 4.4.
Comorbid diseases were present in 270 subjects (47.9%). Thirty-six subjects (6.3%) had COPD, 29 (5.1%) had asthma, 72 (12.8%) had depression, and 39 (6.9%) had hypertension. PFT showed that 114 subjects (20.2%) had obstructive disease, 111 (19.7%) had small airway obstruction, and 11 (2%) had restrictive disease findings. According to GOLD staging, of the subjects who had obstructive disease, 94 (82.4%) were stage I-II, and 20 (7.6%) were stage III-IV.
The success of smoking cessation for 3 months was 11.3% (64 of 563). Age (50.8 y vs 40.7 y, P Ͻ .001), male sex (71.8% vs 58.9%, P ϭ .042), mean pack-years (34.9 pack-year vs 25.8 pack-year, P Ͻ .001), presence of comorbid diseases (60.9% vs 46.9%, P ϭ .046), presence of COPD (14% vs 5%, P ϭ .01), and the presence of hypertension (14% vs 6%, P ϭ .034) were significantly higher in the quitters compared with non-quitters. There were no differences between the 2 groups in the CO levels in expired air, Fagerström score, anxiety score, and depression score (Table 1) .
When we evaluated the cases according to PFT, 22.8% of the subjects with obstruction on PFT quit smoking, whereas only 8.4% of the subjects without obstruction on PFT quit smoking. The difference between these groups was statistically significant (P Ͻ .001). According to GOLD staging, 22.3% of the stage I-II subjects and 25% of the stage III-IV subjects quit smoking. The difference was not statistically significant (P ϭ .79). The percentage of sub- jects with obstructive disease on PFT was significantly higher (40.6% vs 17.6%, P Ͻ .001), and percent-of-predicted FEV 1 (82.9% vs 89.9%, P ϭ .005), FEV 1 /FVC (72.4 vs 79.0, P Ͻ .001), and FEF 25-75% (63.2 vs 72.9, P ϭ .008) levels were significantly lower in quitters compared with non-quitters ( Table 1 ). The distribution of percent-of-predicted FEV 1 was normal in quitters (Fig. 2) .
A total of 162 subjects (28.8%) came to the follow-up visits after the first interview. Among these subjects, 53 (32.7%) received varenicline, 48 (29.6%) received bupropion, and 61 (37.7%) received nicotine replacement therapy. The remaining 401 subjects (71.2%) did not attend the follow-up visits after the first interview. Age (45.7 y vs 40.4 y, P Ͻ .001); mean pack-years (31.1 pack-years vs 25.2 pack-years, P Ͻ .001); and the percentage of COPD, hypertension, and the presence of obstruction on PFT (P ϭ .044, .045, and .001, respectively) were significantly higher in subjects who came to the follow-up visits. In addition, these subjects had significantly lower percent-ofpredicted FEV 1 , FEV 1 /FVC, and FEF 25-75% on PFT (P ϭ .016, P Ͻ .001, and P Ͻ .001, respectively). Adverse effects of the smoking cessation therapy were observed in 26 subjects (16%) who received treatment.
The smoking cessation rate for 3 months was 39.5% in the subjects who received treatment. Age, male sex, mean pack-years, and the presence of obstruction on PFT were significantly higher in the quitters compared with the nonquitters; on the other hand, these subjects had significantly lower FEV 1 /FVC (P Ͻ .001, P ϭ .005, P ϭ .01, P ϭ .01, and P ϭ .01, respectively) ( Table 2) .
Logistic regression analysis for the confounding variables showed that age (P ϭ .001) and the presence of obstruction on PFT (P ϭ .02) were independent vari- Table 3) .
Discussion
In this study, we found that the smoking cessation rate for 3 months was 11.3% for all of the subjects who were admitted to our smoking cessation clinic and 39.5% for the treated subjects. Age, male sex, mean pack-years, presence of comorbid disease (COPD and hypertension), and obstruction on PFT were significantly higher, and PFT levels were significantly lower in the subjects who quit smoking. Moreover, the success rate of smoking cessation after 3 months was significantly higher in subjects with obstructive disease (22.8%), compared with subjects without obstructive disease (8.4%). Given the contradictory results in previous studies, we believe that our current study makes an important contribution to the literature.
It has been known that smoking causes COPD, and quitting smoking prevents COPD progression. 2, 3 Jiménez-Ruiz et al 12 have previously addressed the question of whether COPD makes the process of smoking cessation easier. They found that subjects with COPD had higher 25-75% .11
PFT ϭ pulmonary function testing FEF 25-75% ϭ forced expiratory flow during the middle half of the FVC maneuver levels of nicotine addiction, compared with healthy smokers, and these subjects did not have higher motivation for smoking cessation. In another study, authors found that subjects who quit smoking had more advanced age and lower percent-of-predicted FEV 1 and FEV 1 /FVC ratios. 13 On the other hand, many patients with COPD continue their lives for a long time without realizing their condition. Thus, spirometric measurement is important for patients who apply to smoking cessation clinics. Previous studies have yielded contradictory results regarding the effect of informing subjects about an obstruction, which is determined by spirometry, on smoking cessation success rates. Loss et al 19 conducted one of the earliest studies in this field at the end of the 1970s. This study showed that sharing information with subjects about early airway obstruction, when determined using detailed pulmonary functions tests, made no significant contribution to the smoking cessation success rate in young adults without the long-term support of a doctor. 19 Other studies indicated that the smoking cessation success rate was higher in subjects with pathology on PFT. [29] [30] [31] Two randomized controlled studies in the 1990s also found that abnormal PFT findings contributed to the success of smoking cessation. 32, 33 In a more recent randomized controlled study, the authors concluded that low spirometric values did not increase the success of smoking cessation. 20 Górecka et al 14 carried out a prospective, randomized controlled study and found that subjects with moderate and/or severe obstruction had the highest success rate. In addition, their results showed that subjects with advanced age and subjects with a lower level of smoking had a better success rate. In this study, the authors informed the subjects about spirometry, provided them with booklets, and reevaluated the subjects at the end of the 1-y period. 14 In a similar study, subjects underwent spirometric measurements, and the subjects with obstruction were informed about their conditions and scheduled for a follow-up. One year later, the success rate of smoking cessation was significantly higher in those subjects with obstruction and the subjects with less nicotine addiction. 15 Two other studies also found similar results. 16, 17 In all of these studies, spirometric measurements were performed, and the success of smoking cessation (without pharmacologic treatment) over the long term, was evaluated. A review 21 showed that there is insufficient evidence to deduce that spirometry increases the success rate of smoking cessation. In 2008, Parkes 18 performed spirometric measurements on 561 smokers. For the first group of subjects, the lung age was calculated according to the study by Fletcher, 3 and subjects were informed about the results. On the other hand, only spirometric measurements were performed for subjects in the second group, and lung age was not calculated. At the end of the first year, the success of smoking cessation was 13.6% in the first group and 6.4% in the control group. The authors concluded that calculating lung age and explaining it to subjects increased the success rate of smoking cessation. The Cochrane meta-analysis, 22 which examined the effects of recently reported biomedical risk determiners on the smoking cessation success rate, showed that the study by Parkes et al 18 was the only one indicating the contribution of PFTs to smoking cessation success rates; however, there was not sufficient evidence to make a positive contribution.
Our study was not a randomized controlled study. All subjects who had obstruction on PFT were informed about their condition, and all subjects who had normal spirometry results were also informed that they had normal results. The success of 3-month smoking cessation was 22.8% in subjects with abnormal PFT findings and 8.4% in subjects with normal PFT findings. This difference was statistically significant (P Ͻ .001). However, smoking cessation rates were not different between the subjects with mild to moderate obstruction (GOLD I-II) and the subjects with severe to very severe obstruction (GOLD III-IV) (22.3% vs 25%). This result showed that not only having symptoms but also having been informed about their conditions affected subjects' smoking cessation success. Similar to Górecka et al, 14 we found that subjects who quit smoking had more advanced age and lower percent-ofpredicted FEV 1 , FEV 1 /FVC, and FEF 25-75% , compared with non-quitters. Contrary to the findings of Górecka et al 14 and Bednarek et al, 15 the proportion of heavy smokers (ie, subjects with a higher number of pack-years) was higher in the quitters. When we considered comorbid diseases, the frequencies of COPD and hypertension were significantly higher in the quitters, whereas there were no significant differences in the frequency of depression and anxiety/depression scores. Similarly, Fagerström 34 have found that the presence of comorbid diseases increased the success of smoking cessation. Logistic regression analysis showed that age and the presence of obstruction on PFT were independent variables for smoking cessation success. It is not surprising to find advanced age and lower spirometric levels co-existing together, since the incidence of COPD is higher in males and older people. 35 According to a meta-analysis which evaluated smoking cessation strategies in subjects with COPD, pharmacologic therapy with behavioral treatment shows a conspicuous increase in the success rate. 11 In our study, the overall success rate of smoking cessation was 11.3%, whereas this rate was 39.5% for the subjects who received pharmacologic treatment and attended follow-ups. It seems that the subjects who received pharmacologic therapy that was prescribed by the attending physician and paid for the treatment costs were more determined to succeed. Age, mean pack-years, comorbid diseases, and the presence of obstruction on PFT were significantly higher in these subjects. We thought that having the symptoms of airway obstruction or knowing this condition might have affected their decision. On the other hand, we believe that the reason why all of the subjects did not receive treatment could be associated with the lack of financial cover by the Social Security Institution. Our center is a unit of a public hospital, and patients who apply to our clinic have low incomes. Despite the fact that all subjects were informed about the importance of pharmacologic treatment, they could not cover the costs of medications, and as a result, such subjects did not show up for follow-up examinations. With regard to the treated subjects, age, male sex, mean pack-years, and the presence of obstruction were higher in the quitters, whereas the FEV 1 /FVC was lower compared with non-quitters. This result also showed that these subjects were more determined about smoking cessation.
The limitations of our research are that it was a singlecenter study, so the results cannot be generalized, and that it was also a retrospective cohort study, so the subjects who did not show up for follow-up visits were considered non-quitters. Some of the subjects who did not show up for follow up visits might have quit but were assumed to be non-quitters.
Conclusion
Advanced age and the presence of obstruction on PFT increase the success of smoking cessation. All patients who apply to the smoking cessation out-patient clinic should have pulmonary function tests performed and be informed about their condition. More randomized controlled studies are needed on this subject. We believe that if all patients are supported and encouraged more at smoking cessation clinics and the costs of their pharmacologic treatment are covered by the Social Security Institution, smoking cessation success will increase.
